Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 23rd Annual Global

Terence Flynn
Equity Analyst

Great. Good morning, everybody. I’m Terence Flynn, Morgan Stanley’s U.S. biopharma analyst, and I’m very pleased to be hosting Regeneron to kick off our 23rd Annual Global Healthcare Conference this morning. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Today from the company, we have Len Schleifer, who’s the Board Co-Chair, President and CEO; Marion McCourt, Head of Commercial; and Chris Fenimore, the company’s CFO. With that, I’m going to turn it over to Chris, and then go over to Len for opening remarks.

Christopher Fenimore
Executive VP of Finance & CFO

Thanks, Terence. Real quick. I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Leonard Schleifer
Co-Founder, President, CEO & Co-Chairman

Thanks, Chris, and thanks, Terence, for having us here. It’s good to be at the 23rd Morgan Stanley Conference. Chris started out with his statement about forward-looking statements. And usually, we kind of look backward, but I’ve decided today, we’re going to really look forward and talk to you about what the